Shukra Pharmaceuticals Fair Value
Shukra Pharmaceuticals fair value. Shukra Pharmaceuticals (SHUKRAPHAR) average fair value is ₹19.97 across 4 valuation models — P/B Based Valuation, Dividend Discount Model, Price-to-Sales Valuation, Asset-Based Valuation, vs a current market price of ₹70.49 (-71.67%), fair value range ₹0.01–₹58.7. Explore Shukra Pharmaceuticals intrinsic price to estimate fundamental worth using multiple valuation models.
Fair Value Analysis Export
SHUKRAPHAR Fair Value vs Current Price — Valuation Summary
SHUKRAPHAR average fair value, fair value range, price gap and valuation status across 4 models: P/B Based Valuation, Dividend Discount Model, Price-to-Sales Valuation, Asset-Based Valuation. For live price and a broader fundamental view, visit Shukra Pharmaceuticals stock price NSE.
P/B Based Valuation
Dividend Discount Model
Price-to-Sales Valuation
Asset-Based Valuation
SHUKRAPHAR Fair Value Analysis — Data Sources & Coverage
Shukra Pharmaceuticals financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. Check Shukra Pharmaceuticals marketcap in USD to track the company's total market size over time.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
SHUKRAPHAR vs Healthcare Sector Peers — P/E, P/B & Market Cap
Shukra Pharmaceuticals P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 35.85 | 7.38 | ₹37,156 |
| Syngene International | SYNGENE | 68.69 | 3.13 | ₹15,000 |
| Divis Laboratories | DIVISLAB | 87.22 | 15.22 | ₹253,522 |
| Aurobindo Pharma | AUROPHARMA | 25.97 | 2.54 | ₹96,479 |
| Sat Kartar Life | SATKARTAR | 16.56 | 4.14 | ₹307 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.